For COVID-19 and vaccination updates, view our information for the community. If you're experiencing symptoms, call your primary care provider.

Decorative dot pattern background image.
Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image.

Blood Cancer

Blood Cancer

Alliance A041701

Official Title: A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
Study Purpose: To compare the usual treatment alone to using uproleselan plus the usual treatment.
Status: Suspended
Blood Cancer

Alliance A041702

Official Title: A Randomized Phase III study of Ibrutinib Plus Obinutuzumab versus Ibrutinib plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70 years of age) with Chronic Lymphocytic Leukemia (CLL)
Study Purpose: To compare the usual treatment alone (Ibrutinib plus Obinutuzumab) to using Venetoclax plus the usual treatment. The addition of Venetoclax to the usual treatment could prevent chronic lymphocytic leukemia from returning.
Status: Recruiting
Blood Cancer

Alliance A051701

Official Title: Testing The Addition Of A New Anti-Cancer Drug Venetoclax To Usual Chemotherapy For High Grade Cell Lymphomas
Study Purpose: To determine if adding a new drug, venetoclax, to the usual combination of drugs can lower the chance of lymphoma returning or getting worse. Also, to find out if this approach is better or worse than the usual approach for lymphoma.
Status: Suspended
Blood Cancer

CIBMTR Research Database

Official Title: Center for International Blood and Marrow Transplant Research: Protocol for a Research Database for Hematopoietic Cell Transplantation and Cellular Therapies
Study Purpose: To gather health information from patients receiving stem cell transplants that can be used to find ways to make stem cell transplants work better. 
Status: Recruiting
Blood Cancer

SWOG S1712

Official Title: A randomized phase II study of ruxolitinib (NCS-752295) in combination with BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia (CML) patients with molecular evidence of disease
Study Purpose: The purpose of this study is to compare the good and bad effects of adding the study drug ruxolitinib to the usual chemotherapy (called TKI, which is either dasatinib or nilotinib) with the good and bad effects of using TKI alone.
Status: Recruiting
Blood Cancer

SWOG S1803

Official Title: Phase III study of daratumumab/rHuPH20 (NSC-810307) + lenalidomide or lenalidomide as post-autologous stem cell transplant maintenance therapy in patients with multiple myeloma (MM) using minimal residual disease to direct therapy duration (dramatic study)
Study Purpose: The purpose of this part of the study (screening consent) is to allow the study doctor to follow the progress through transplant and see if the treatment portion is appropriate.   
Status: Recruiting